Publications by authors named "Hannah Lathrop"
Article Synopsis
- Pancreatic cancer is very tough to treat, with only 13% of patients surviving for five years, so better treatments are needed.
- CD200 is a protein that can influence the immune response and is found in high amounts in pancreatic tumors, which seems to make the situation worse.
- Scientists found that high levels of a form of CD200 in blood are linked to poorer survival rates, suggesting that targeting CD200 might help create new treatment strategies for pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high metastasis and therapeutic resistance. Activating transcription factor 4 (ATF4), a master regulator of cellular stress, is exploited by cancer cells to survive. Prior research and data reported provide evidence that high ATF4 expression correlates with worse overall survival in PDAC.
View Article and Find Full Text PDF